stockrowDanaher Corporation
DHR Healthcare Diagnostics & Research
Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024.
- Revenue
- +8.28%
- EPS
- +36.7%
- Free cash flow
- +19.1%
- Total debt
- +44.9%
Quarter to September 2026, against a year earlier
Follow DHR
Alert me
Danaher Corporation (DHR) EBITDA
Danaher Corporation's EBITDA for fiscal 2025 was $7.1B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $8.0B. Over the past ten years it has ranged from $3.0B (fiscal 2015) to $9.7B (fiscal 2022); the current reading is higher than 64% of that period. EBITDA has fallen for 3 consecutive fiscal years. Danaher Corporation ranks 2nd of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $7.1B | (1.42%) |
| FY2024 | $7.2B | (1.84%) |
| FY2023 | $7.4B | (23.71%) |
| FY2022 | $9.7B | 13.77% |
| FY2021 | $8.5B | 31.49% |
| FY2020 | $6.5B | 44.98% |
| FY2019 | $4.5B | 5.32% |
| FY2018 | $4.2B | 14.74% |
| FY2017 | $3.7B | (4.51%) |
| FY2016 | $3.9B | 26.96% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $2.1B | 11.90% |
| Jun 2026 | $1.8B | (7.05%) |
| Mar 2026 | $2.0B | (7.25%) |
| Dec 2025 | $2.1B | 19.65% |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| TMO Thermo Fisher Scientific Inc. compare | $11.6B |
| DHR Danaher Corporation | $8.0B |
| IQV IQVIA Holdings Inc. compare | $3.5B |
| A Agilent Technologies, Inc. compare | $1.9B |
| IDXX IDEXX Laboratories, Inc. compare | $1.7B |
| MTD Mettler-Toledo International, Inc. compare | $1.3B |
| ILMN Illumina, Inc. compare | $1.2B |
| WAT Waters Corporation compare | $942.8M |
| NTRA Natera, Inc. compare | −$223.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on DHR
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement